Theocharis Panaretakis, M.D.
Department of Genitourinary Medical Oncology, Division of Cancer Medicine
Education & Training
Degree-Granting Education
| 2003 | Karolinska Institutet, Solnavagen, USA, PHD, Experimental Oncology |
| 1997 | University of Sussex, Falmer, GBR, BS, Biochemistry |
Experience & Service
Academic Appointments
Associate Professor, Department of Genitourinary Medical Oncology - Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - Present
Visiting Associate Professor, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2019
Principal investigator, Department of Department of Oncology-Pathology, Karolinska Institutet, Stockholm, 2010 - 2016
Assistant Professor, Department of Department of Oncology-Pathology, Karolinska Institutet, Stockholm, 2009 - Present
Associate Professor, Karolinska Institutet, Stockholm, 2009 - Present
Selected Publications
Peer-Reviewed Articles
- Corn PG, Zhang M, Nogueras-Gonzalez GM, Xiao L, Zurita AJ, Subudhi SK, Tu SM, Aparicio AM, Coarfa C, Rajapakshe K, Huang S, Navone NM, Lin SH, Wang G, Ramachandran S, Titus MA, Panaretakis T, Gallick GE, Efstathiou E, Troncoso P, Logothetis C. A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer. Clin Cancer Res 26(5):990-999, 2020. e-Pub 2020. PMID: 31941830.
- Koinis F, Corn P, Parikh N, Song J, Vardaki I, Mourkioti I, Lin SH, Logothetis C, Panaretakis T, Gallick G. Resistance to MET/VEGFR2 Inhibition by Cabozantinib Is Mediated by YAP/TBX5-Dependent Induction of FGFR1 in Castration-Resistant Prostate Cancer. Cancers (Basel) 12(1), 2020. e-Pub 2020. PMID: 31963871.
Grant & Contract Support
| Title: | Response Evaluation of Finite Systemic Therapy with Advanced Androgen Signaling Inhibition and Radiation Therapy for Oligorecurrent Prostate Cancer (RESTART) |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-Investigator |